THE BIOLOGY OF LUNG CANCER-- FDG AND FLUOROTHYMIDINE PET
肺癌的生物学--FDG和氟胸苷宠物
基本信息
- 批准号:6685859
- 负责人:
- 金额:$ 37.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-01-12 至 2005-12-31
- 项目状态:已结题
- 来源:
- 关键词:DNA replicationbioimaging /biomedical imagingbiomarkercell proliferationclinical researchdeoxyglucoseflow cytometryglucose metabolismhuman subjectimmunocytochemistrylung imaging /visualization /scanningmetastasisneoplasm /cancer classification /stagingneoplasm /cancer relapse /recurrenceneoplastic processnonsmall cell lung canceroutcomes researchpositron emission tomographypostoperative statepreoperative stateprognosisradiation dosage
项目摘要
The objective of the proposed studies is to investigate quantitative [F- 18]fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) as a measure of non-small cell lung cancer (NSCLC) aggressiveness in vivo (i.e. grading) and to make comparisons with patients' outcomes and with specimen-derived measures of cellular proliferation previously shown to predict poor outcome (S-phase fraction, Ki-67 index). We postulate that, in clinically resectable NSCLC patients, pre-operative FDG PET will show that tumors with higher FDG uptake: (a) will recur sooner after surgical resection than same stage tumors with low uptake; (b) are more likely to have mediastinal or distal metastatic disease than tumors of the same clinical stage but low uptake; (c) have higher S-phase fraction of Ki-67 scores in their resected specimen. The specific aims of the proposal are: (1) Perform whole-body pre- operative FDG PET imaging and correlate FDG uptake in primary NSCLC with outcome. FDG uptake will be quantified by the following methods that will be compared. Standardized Uptake Value (SUV) and SKM-FDGMR (FDG Metabolic Rate determined by a Simplified Kinetic Method). (2) Perform whole-body pre-operative FDG PET imaging and correlate FDG uptake (quantified as SUV and SKM-FDGMR) in primary NSCLC with disease extent as demonstrated by PET and surgical staging. (3) Correlate pre-operative FDG uptake in primary NSCLC with markers of cellular proliferation measured from the resected specimen and previously shown to predict poor outcome. Outcome will be measured by recurrence-free survival, time-to recurrence and survival. In summary, by studying NSCLC patients pre-operatively, prior to any form of chemotherapy or radiotherapy, we will gain valuable information about the biology of lung cancer, the leading cause of cancer death in the United States. By performing a biologic grading of resectable NSCLC with FDG PET, we will predict which patients will have a worse outcome. This information will allow individualized therapy.
拟议研究的目的是研究定量[F- 18]氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)作为体内非小细胞肺癌(NSCLC)侵袭性的指标(即分级),并与患者结局和先前显示可预测不良结局的细胞增殖指标(S期分数,Ki-67指数)进行比较。我们假设,在临床可切除的NSCLC患者中,术前FDG PET将显示具有较高FDG摄取的肿瘤:(a)在手术切除后比具有低摄取的相同阶段肿瘤更早复发;(B)比具有相同临床阶段但低摄取的肿瘤更可能具有纵隔或远端转移性疾病;(c)在其切除标本中具有较高的Ki-67评分的S期分数。该提案的具体目标是:(1)进行全身术前FDG PET成像,并将原发性NSCLC的FDG摄取与结局相关联。FDG摄取将通过以下方法进行定量,并进行比较。标准化摄取值(SUV)和SKM-FDGMR(通过简化动力学方法测定的FDG代谢率)。(2)进行全身术前FDG PET成像,并将原发性NSCLC中的FDG摄取(量化为SUV和SKM-FDGMR)与PET和手术分期显示的疾病程度相关联。(3)将原发性非小细胞肺癌术前FDG摄取与从切除标本中测量的细胞增殖标记物相关联,并且先前显示预测不良结局。结果将通过无复发生存期、复发时间和生存期来衡量。总之,通过在术前研究NSCLC患者,在任何形式的化疗或放疗之前,我们将获得关于肺癌生物学的有价值的信息,肺癌是美国癌症死亡的主要原因。通过FDG PET对可切除的NSCLC进行生物学分级,我们将预测哪些患者的预后更差。这些信息将允许个性化治疗。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
- DOI:
- 发表时间:2003-12
- 期刊:
- 影响因子:0
- 作者:H. Vesselle;É. Turcotte;L. Wiens;D. Haynor
- 通讯作者:H. Vesselle;É. Turcotte;L. Wiens;D. Haynor
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.
正电子发射断层扫描显示肺癌增殖与[F-18]氟脱氧葡萄糖摄取相关。
- DOI:
- 发表时间:2000
- 期刊:
- 影响因子:0
- 作者:Vesselle,H;Schmidt,RA;Pugsley,JM;Li,M;Kohlmyer,SG;Vallires,E;Wood,DE
- 通讯作者:Wood,DE
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
3脱氧-3-[(18)F]氟胸苷 ([(18)F]FLT) 作为人体增殖成像示踪剂的体内验证:正电子发射断层扫描 [(18)F]FLT 摄取与
- DOI:
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:Vesselle,Hubert;Grierson,John;Muzi,Mark;Pugsley,JeffreyM;Schmidt,RodneyA;Rabinowitz,Peter;Peterson,LanellM;Vallières,Eric;Wood,DouglasE
- 通讯作者:Wood,DouglasE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HUBERT J VESSELLE其他文献
HUBERT J VESSELLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HUBERT J VESSELLE', 18)}}的其他基金
Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
肺癌预后:FLT PET 和 DNA 高甲基化
- 批准号:
6956139 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
肺癌预后:FLT PET 和 DNA 高甲基化
- 批准号:
7101959 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
肺癌预后:FLT PET 和 DNA 高甲基化
- 批准号:
7435185 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
肺癌预后:FLT PET 和 DNA 高甲基化
- 批准号:
7626662 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
肺癌预后:FLT PET 和 DNA 高甲基化
- 批准号:
7249430 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
FLT PET to Plan the Best Therapy for Lung Cancer
FLT PET 规划肺癌最佳治疗方案
- 批准号:
7059330 - 财政年份:2004
- 资助金额:
$ 37.62万 - 项目类别:
FLT PET to Plan the Best Therapy for Lung Cancer
FLT PET 规划肺癌最佳治疗方案
- 批准号:
6762943 - 财政年份:2004
- 资助金额:
$ 37.62万 - 项目类别:
FLT PET to Plan the Best Therapy for Lung Cancer
FLT PET 规划肺癌最佳治疗方案
- 批准号:
6874458 - 财政年份:2004
- 资助金额:
$ 37.62万 - 项目类别:
FLT PET to Plan the Best Therapy for Lung Cancer
FLT PET 规划肺癌最佳治疗方案
- 批准号:
7366996 - 财政年份:2004
- 资助金额:
$ 37.62万 - 项目类别:
FLT PET to Plan the Best Therapy for Lung Cancer
FLT PET 规划肺癌最佳治疗方案
- 批准号:
7217252 - 财政年份:2004
- 资助金额:
$ 37.62万 - 项目类别: